Intrathecal anti-IL-6 antibody and IgG attenuates peripheral nerve injury-induced mechanical allodynia in the rat: Possible immune modulation in neuropathic pain

Brain Research

Volumn 879, Issue 1-2, 2000, Pages 216-225

  Arruda, Janice L ^a   Sweitzer, Sarah ^a   Rutkowski, Maria D ^a   Deleo, Joyce A ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Astrocytes; Glial fibrillary acidic protein; Interleukin 6; IVIg therapy; Microglia; Neuropathic pain; Pain modulation: pharmacology; Sensory systems

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; NEUTRALIZING ANTIBODY;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GOAT; HYPERALGESIA; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; MALE; MICROGLIA; MOTONEURON; NERVE INJURY; NEURALGIA; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL NERVE;

ANIMALS; ANTIBODIES; IMMUNOGLOBULIN G; INJECTIONS, SPINAL; INTERLEUKIN-6; MALE; MICROGLIA; NEURALGIA; NEUROGLIA; PAIN; PHYSICAL STIMULATION; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD; SPINAL NERVES;

EID: 0034613224     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(00)02807-9     Document Type: Article

References (49)

1. Abe Y., Horiuchi A., Miyake M., Kimura S. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol. Rev. 139:1994;5-19.
2. Akaneya Y., Takahashi M., Hatanaka H. Interleukin-1β enhances survival and interleukin-6 protects against MPP+ neurotoxicity in cultures of fetal rat dopaminergic neurons. Exp. Neurol. 136:1995;44-52.
3. Arruda J.L., Colburn R.W., Rickman A.J., Rutkowski M.D., DeLeo J.A. Increase of interleukin-6 mRNA in the spinal cord following peripheral nerve injury in the rat: potential role of IL-6 in neuropathic pain. Mol. Brain Res. 62:1998;228-235.
4. Bastam M., Dalakas M.C. High dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J. Clin. Invest. 94:1994;1729-1735.
5. Berkman S.A., Lee M.L., Gale R.P. Clinical uses of intravenous immunoglobulins. Ann. Intern. Med. 112:1990;278-292.
6. Colburn R.W., DeLeo J.A., Rickman A.J., Yeager M.P., Kwon P., Hickey W.F. Dissociation of microglial activation and neuropathic pain behaviors following peripheral nerve injury in the rat. J. Neuroimmunology. 79:1997;163-175.
7. Colburn R.W., Rickman A.J., DeLeo J.A. The effect of site and type of nerve injury on spinal glial activation and neuropathic pain behavior. Exp. Neurol. 157:1999;289-304.
8. Covino B.G., Dubner R., Gybels J., Losterlitz H.W., Liebeskind J.C., Sternbach R.A., Vylicky L., Yamamura H., Zimmerman M. Ethical standards for investigations of experimental pain in animals. Pain. 9:1980;141-143.
9. Dalakas M. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology. 51:1998;S1-S8.
10. Dalakas M.C. Clinical relevance of IVIg in the modulation of the complement-mediated tissue damage: implication in dermatomyositis, Guillain Barre syndrome and myasthenia gravis. Kazatchkine M., Morel A. Intravenous Immunoglobulin Research and Therapy. 1996;89-93 Parthenon Publishing, London.
11. Dalakas M.C. Experience with IVIg in the treatment of inflammatory myopathies. Kazatchkine M., Morel A. Intravenous Immunoglobulin Research and Therapy. 1996;275-284 Parthenon Publishing, London.
12. Dalakas M.C. Intravenous immunoglobulin therapy for neruological diseases. Ann. Intern. Medicine. 126:1997;721-730.
13. DeLeo J.A., Colburn R.W., Nichols M., Malhotra A. Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. J. Interferon Cytokine Res. 16:1996;695-700.
14. DeLeo J.A., Colburn R.W., Rickman A.J. Cytokine and growth factor immunohistochemical spinal profiles in two animal models of mononeuropathy. Brain Res. 759:1997;50-57.
15. Dibirdik I., Durak N., Kislauglu E., Kutluay T., Aytemiz C. Effects of prophylactic intravenous immunoglobulin-G therapy on humoral and cellular immune components and their functions in burned patients. Burns. 21:1995;130-135.
16. Dwyer J.M. Manipulating the immune system with immune globulin. New England J. Med. 326:1992;107-116.
17. Gauldie J., Richard C., Harnish D., Lansdorp P., Baumann H. Interferon β2/B-cell stimulating factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the acute phase response in liver cells. Proc. Natl. Acad. Sci. USA. 84:1987;7251-7259.
18. Geiss A., Varadi E., Steinbach K., Bauer H., Anton F. Psychoneuroimmunological correlates of persisting sciatic pain in patients who underwent discectomy. Neurosci. Lett. 237:1997;65-68.
19. Hama T., Kushima Y., Miyamoto M., Kubota M., Takei N., Hatanaka H. Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures. Neuroscience. 40:1991;445-452.
20. Hansen M.B., Svenson M., Diamant M., Bendtzen K. Anti-interleukin-6 antibodies in normal human serum. Scand. J. Immunol. 33:1991;777-781.
21. Hirohata H., Kiyama H., Kishimoto T., Taga T. Accelerated nerve regeneration in mice by upregulated expression of interleukin 6 (IL-6) and IL-6 receptor after trauma. J. Exp. Med. 183:1996;2627-2634.
22. Huang Z.F., Massey J.B., Via D.P. Differential regulation of cyclooxygenase (COX-2) mRNA stability by interleukin-1 beta and tumor necrosis factor-alpha in human in vitro differentiated macrophages. Biochem. Pharmacol. 59:2000;187-194.
23. Ikeda K., Iwasaki Y., Shiojima T., Kinoshita M. Neuroprotective effects of various cytokines on developing spinal motorneurons following axotomy. J. Neurol. Sci. 135:1996;109-113.
24. Inoue A., Ikoma K., Morioka N., Kumagia K., Hashimoto T., Hide I., Nakata Y. Interleukin-1 beta induces substance P release from primary afferent neurons through the cyclooygenase-2 system. J. Neurochem. 73:1999;2206-2213.
25. Imbach P., Barandum S., d'Apuzzo V., Baumgartner C., Hirt A., Morell A., Rossi E., Schoni M., Vest M., Wagner H.P. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1:1981;1228-1231.
26. Kurlander R.J. Reversible and irreversible loss of Fc receptor function of human monocytes as a consequence of interaction with immunoglobulin G. J. Clin. Invest. 66:1980;773-781.
27. Kurlander R.J., Hall J. Comparison of intravenous gammaglobulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice. J. Clin. Invest. 77:1986;2010-2018.
28. Lee F.D. The role of interleukin-6 in development. Dev. Biol. 151:1992;331-338.
29. Ma T., Zhu X. Interleukin-6 increases the levels of cyclic GMP and nitrite in rat hippocampal slices. Eur. J. Pharmacology. 321:1997;343-347.
30. Ma T.C., Zhu X.Z. Effects of intrahippocampal infusion of interleukin-6 on passive avoidance and nitrite and prostaglandin levels in the hippocampus in rats. Arzneimittel-Forschung. 50:2000;227-231.
31. Marz P., Herget T., Lang E., Otten U., Rose-John S. Activation of gp130 by IL-6/soluble IL-6 receptor induces neuronal differentiation. Eur.J. Neurosci. 12:1997;2765-2773.
32. Meller S.T., Dykstra C., Grsybicki D., Murphy S., Gebhart G.F. The possible role of glia in nociceptive processing and hyperalgesia in the spinal cord of the rat. Neuropharmacology. 33:1994;1471-1478.
33. Murphy P.G., Ramer M.S., Borthwick L., Gauldie J., Richardson P.M., Bisby M.A. Endogenous interleukin-6 contributes to hypersensitivity to cutaneous stimuli and changes in neuropeptids associated with chronic nerve constriction in mice. Eur. J. Neurosci. 11:1999;2243-2253.
34. Nagashima M., Matsushima M., Matsuoka H., Ogawa A., Okumura N. High dose gammaglobulin therapy for Kawasaki disease. J. Pediatrics. 110:1987;710-712.
35. Nakafuku M., Satoh T., Kaziro Y. Differentiation factors, including nerve growth factor, fibroblast growth factor, and interleukin-6, induce an accumulation of an active ras-GTP complex in rat pheochromocytoma PC12 cells. J. Biol. Chem. 267:1992;19448-19454.
36. Newburger J.W., Takahashi M., Burns J.C., Beiser A.S., Chung K.I., Duffy C.E., Glode M.P., Mason W.H., Reddy V., Sanders S.P., et al. The treatment of Kawasaki's syndrome with intravenous gamma globulin. New England J. Med. 315:1986;341-347.
37. Oka T., Oka K., Hosoi M., Hori T. Intracerebroventricular injection of interleukin-6 induces thermal hyperalgesia in rats. Brain Res. 692:1995;123-128.
38. Pap T., Reinhold D., Kekow J. Effects of intravenous immunoglobulins on disease activity and cytokine plasma levels in rheumatoid arthritis. Can. J. Rheumatol. 27:1998;157-159.
39. Ramer M.S., Murphy P.G., Richardson P.M., Bisby M.A. Spinal nerve lesion-induced mechanoallodynia and adrenergic sprouting in sensory ganglia are attenuated in interleukin-6 knockout mice. Pain. 78:1998;115-121.
40. Ross C., Svenson M., Hansen M.B., Vejlsgaard G.L., Bendtzen K. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. J. Clin. Invest. 95:1995;1974-1978.
41. Ross C., Svenson M., Nielsen H., Lundsgaard C., Hansen M.B., Bendtzen K. Increased in vivo antibody activity against interferon alpha, interleukin-1alpha, and interleukin-6 after high-dose Ig therapy. Blood. 90:1997;2376-2380.
42. Schuller E., Goverts A. First results of immuno-therapy with immunoglobulin G in multiple sclerosis patients. Eur. Neurol. 22:1983;205-212.
43. Sekul E., Cupler E., Dalakas M. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Annal. Int. Med. 121:1994;259-262.
44. Serou M.J., DeCoster M.A., Bazan N.G. Interleukin-1 beta activated expression of cyclooxygenase-2 and inducible nitric oxide synthase in primary hippocampal neuronal culture: Platelet activating factor as a preferential mediator of cyclooxegenase-2 expression. J. Neurosci. Research. 58:1999;593-598.
45. Sommer C., Petrausch S., Lindenlaub T., Toyka K. Neutralizing antibodies to interleukin 1-receptor reduce pain associated behavior in mice with experimental neuropathy. Neurosci. Lett. 270:1999;25-28.
46. Svenson M., Hansen M.B., Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J. Clin. Invest. 92:1993;2533-2539.
47. S. Sweitzer, D. Martin, J.A. DeLeo, Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibit an anti-allodynic action in a rat model of neuropthic pain, Neuroscience, submitted.
48. Takei S., Arora Y.K., Walker S.M. Intravenous immunoglobulin contains specific antibodies inhibitory of activation of T cells by staphylococcal toxin superantigen. J. Clin. Invest. 91:1993;602-607.
49. van der Meche F.G., Kleijweg R.P., Meulster J. Intravenous gammaglobulin (IVGG) versus plasmapheresis trial in patients with acute Guillain-Barre Syndrome (GBS). Clin. Neurol. Neurosurgery. 89:1987;62-63.